We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pharma’s friend?

17 November 2014 By Robert Cyran

The activist will reap more than $2 bln from Actavis buying Allergan. It’s a steep price – cost cuts alone cannot justify the premium paid. And losing bidder Valeant has been hauled over the coals. It will, at least, get a $400 mln consolation prize from former ally Ackman.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)